Can­cer drug to treat dwarfism? Aban­doned No­var­tis as­set snagged by Bridge­Bio’s QED Ther­a­peu­tics

Bridge­Bio is snatch­ing a re­cent­ly-aban­doned can­cer pro­gram off No­var­tis’ shelves, hand­ing the as­set to a spin­out com­pa­ny with un­usu­al plans for the drug.

The new­ly-li­censed prod­uct — called in­fi­gra­tinib or BGJ398 — was in Phase II tri­als at No­var­tis for pa­tients with bile duct can­cer with FGFR fu­sions. Al­though the drug showed mean­ing­ful clin­i­cal ac­tiv­i­ty ear­ly in the tri­al, No­var­tis de­cid­ed to dump the drug last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER